| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From MINCEP Epilepsy Care (Drs. Tran, Leppik, and Blesi), Department of Neurology (Drs. Tran, Leppik, and Sathanandan), and College of Pharmacy (Drs. Leppik and Remmel), University of Minnesota, Minneapolis.
Address correspondence and reprint requests to Dr. T.A. Tran, MINCEP Epilepsy Care, 5775 Wayzata Boulevard, Suite 200, Minneapolis, MN 55416.
Objective: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy.
Methods: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg·day]) of LTG was calculated by dose/level/weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student–Newman–Keuls test, and the paired Student’s t-test.
Results: An increase in apparent clearance (>65%) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced.
Conclusion: Pregnancy increases LTG clearance by >50%. This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.
This article has been cited by other articles:
|
|
 |
|
  E. Nordmo, L. Aronsen, K. Wasland, L. Smabrekke, and S. Vorren Severe Apnea in an Infant Exposed to Lamotrigine in Breast Milk Ann. Pharmacother., November 1, 2009; 43(11): 1893 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Wegner, P. M. Edelbroek, S. Bulk, and D. Lindhout Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives Neurology, October 27, 2009; 73(17): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Harden, P. B. Pennell, B. S. Koppel, C. A. Hovinga, B. Gidal, K. J. Meador, J. Hopp, T. Y. Ting, W. A. Hauser, D. Thurman, et al. Practice Parameter update: Management issues for women with epilepsy--Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society Neurology, July 14, 2009; 73(2): 142 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Pennell, L. Peng, D. J. Newport, J. C. Ritchie, A. Koganti, D. K. Holley, M. Newman, and Z. N. Stowe Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency Neurology, May 27, 2008; 70(22_Part_2): 2130 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montouris Importance of monotherapy in women across the reproductive cycle Neurology, December 11, 2007; 69(24_suppl_3): S10 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tomson and V. Hiilesmaa Epilepsy in pregnancy BMJ, October 13, 2007; 335(7623): 769 - 773. [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
|
|
R. Kalviainen and T. Tomson Optimizing treatment of epilepsy during pregnancy Neurology, December 26, 2006; 67(12_suppl_4): S59 - S63. [Abstract] [Full Text]
|
|
|
|
|
|
J. Christensen, A. Sabers, and P. Sidenius Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy Neurology, October 24, 2006; 67(8): 1497 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tomson, G. Luef, A. Sabers, S. Pittschieler, and I. Ohman Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology, October 10, 2006; 67(7): 1297 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The EURAP Study Group Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry Neurology, February 14, 2006; 66(3): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Splinter Pharmacokinetic Properties of New Antiepileptic Drugs Journal of Pharmacy Practice, December 1, 2005; 18(6): 444 - 460. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Chen, D. Beaton, N. Nguyen, K. Senekeo-Effenberger, E. Brace-Sinnokrak, U. Argikar, R. P. Remmel, J. Trottier, O. Barbier, J. K. Ritter, et al. Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus J. Biol. Chem., November 11, 2005; 280(45): 37547 - 37557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M D O'Brien and S K Gilmour-White Management of epilepsy in women Postgrad. Med. J., May 1, 2005; 81(955): 278 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Yonkers, K. L. Wisner, Z. Stowe, E. Leibenluft, L. Cohen, L. Miller, R. Manber, A. Viguera, T. Suppes, and L. Altshuler Management of Bipolar Disorder During Pregnancy The Postpartum Period Focus, April 1, 2005; 3(2): 266 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cunnington, P. Tennis, and the International Lamotrigine Pregnancy Registry S Lamotrigine and the risk of malformations in pregnancy Neurology, March 22, 2005; 64(6): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Hirsch, D. Weintraub, Y. Du, R. Buchsbaum, H. T. Spencer, M. Hager, T. Straka, C. W. Bazil, D. J. Adams, S. R. Resor Jr., et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy Neurology, September 28, 2004; 63(6): 1022 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G -J. de Haan, P. Edelbroek, J. Segers, M. Engelsman, D. Lindhout, M. Devile-Notschaele, and P. Augustijn Gestation-induced changes in lamotrigine pharmacokinetics: A monotherapy study Neurology, August 10, 2004; 63(3): 571 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Yonkers, K. L. Wisner, Z. Stowe, E. Leibenluft, L. Cohen, L. Miller, R. Manber, A. Viguera, T. Suppes, and L. Altshuler Management of Bipolar Disorder During Pregnancy and the Postpartum Period Am J Psychiatry, April 1, 2004; 161(4): 608 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Pennell, D. J. Newport, Z. N. Stowe, S. L. Helmers, J. Q. Montgomery, and T. R. Henry The impact of pregnancy and childbirth on the metabolism of lamotrigine Neurology, January 27, 2004; 62(2): 292 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Pennell Antiepileptic drug pharmacokinetics during pregnancy and lactation Neurology, September 1, 2003; 61(90062): S35 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
A. Sabers, I. Ohman, J. Christensen, and T. Tomson Oral contraceptives reduce lamotrigine plasma levels Neurology, August 26, 2003; 61(4): 570 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Pennell The importance of monotherapy in pregnancy Neurology, June 10, 2003; 60(90114): S31 - 38. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
